'Roche could've earned over 100 times what it cost for rare disease drug'
Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful projects and ongoing research. While the drug remains unaffordable for many in India, Roche offers access programs and free treatment to some patients.
Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful projects and ongoing research. While the drug remains unaffordable for many in India, Roche offers access programs and free treatment to some patients.
